Delineating the factors leading to the development of broadly neutralizing antibodies (bnAbs) during natural HIV-1 infection and dissecting their epitope specificities generates useful information for vaccine design. This is the first longitudinal study to assess the plasma-neutralizing antibody response and neutralizing determinants in HIV-1-infected children from India. We enrolled 26 and followed up 20 antiretroviral therapy (ART)-naïve, asymptomatic, chronic HIV-1-infected children. Five (19.2 %) baseline and 10 (50 %) follow-up plasma samples neutralized !50 % of subtypes A, B and C tier 2 viruses at an ID 50 titre !150. A modest improvement in neutralization breadth and potency was observed with time. At baseline, subtype C-specific neutralization predominated (P=0.026); interestingly, follow-up samples exhibited cross-neutralizing activity. Epitope mapping revealed V3C reactive antibodies with significantly increased Max 50 binding titres in follow-up samples from five infected children; patient #4's plasma antibodies exhibited V3-directed neutralization. A salient observation was the presence of CD4 binding site (CD4bs)-specific NAbs in patient #18 that improved with time (1.76-fold). The RSC3 wild-type (RSC3WT) protein-depleted plasma eluate of patient #18 demonstrated a more than 50% ID 50 decrease in neutralization capacity against five HIV-1 pseudoviruses. Further, the presence of CD4bs-neutralizing determinants in patient #18's plasma was confirmed by the neutralizing activity demonstrated by the CD4bs-directed IgG fraction purified from this plasma, and competition with sCD4 against JRFLgp120, identifying this paediatric donor as a potential candidate for the isolation of CD4bs-directed bnAbs. Overall, we observed a relative increase in plasma-neutralizing activity with time in HIV-1-infected children, which suggests that the bnAbs evolve.
INTRODUCTION
Neutralizing antibodies (NAbs) contribute substantially to an effective immune response against human immunodeficiency virus (HIV-1) [1, 2] . Several passive immunization studies in non-human primates have shown NAbs to confer protection against viral challenge [3] [4] [5] [6] [7] . However, major obstacles to eliciting broad and potent NAbs include the unprecedented diversity of the HIV-1 envelope, evolving glycans and conformational masking of some of the neutralization-determining epitopes, and these are hindering efforts to design an effective vaccine against HIV-1 [8] [9] [10] [11] . The HIV-1 envelope-based immunogens designed so far have failed, despite repeated boosting, to elicit correlates of protection [12] [13] [14] [15] [16] . During natural infection, varied crossneutralizing activity is displayed by plasma antibodies [17] [18] [19] and, interestingly, in a few of the infected individuals [5 % long-term non-progressors (LTNPs) and 1 % elite controllers], a robust antibody response evolves over time that is capable of neutralizing HIV-1 viral isolates of different lineages and subtypes [20] [21] [22] [23] .
Disease progression is faster in HIV-1-infected children compared with adults [24] . Some reports suggest that in the absence of antiretroviral therapy (ART), >50 % of HIV-1-infected children progress rapidly to AIDS or death within the first 2 years of life, while the rest experience similar rates of disease progression to adults [25] [26] [27] . Few studies have been conducted in HIV-1-infected children to assess their immune status [28, 29] and plasma NAb activity [30] [31] [32] , either early in the acute phase (at infancy) [32, 33] , or in the context of mother-child humoral immune response, in non-subtype C
RESULTS

Characteristics of HIV-1-infected children
The demographic profiles of the 20 HIV-1-infected children recruited for the study are provided in Table 1 and summarized in Table S1 (available in the online Supplementary Material). All of the children had acquired HIV-1 through mother-to-child transmission. There were 14 males and 6 females within an age range of 5-17 years. All of the chronic HIV-1-infected children were ART-naïve and asymptomatic (at clinical stage 1 or 2). The median CD4 count for the baseline samples of the infected children was 662 (range=308-1680) cells/cubic millimetre and the median viral load was 34 300 (range=3410-899 000) RNA copies/ml plasma.
Evolution of plasma cross-NAbs
We assessed the breadth and potency of the cross-neutralizing HIV-1-specific plasma antibodies of 20 infected children at baseline and in follow-up samples against a panel of 25 pseudoviruses. A diverse panel of viruses, which included both Indian and non-Indian subtype C as well as non-subtype C viruses, was used in the present study to determine the breadth of the HIV-1-infected plasma samples [40] . Follow-up sampling at an interval of 6 months was completed for 20 children up to the third time-point. For patient #4, the first follow-up sample was collected after 3 months and the other two were collected at 6-month intervals.
We defined the plasma cross-neutralizing activity as the ability to neutralize at least 50 % of the tier 2 viruses of subtypes A, B and C at ID 50 titre !150. The baseline plasma samples of 5 of the 20 (25 %) infected children had HIV-1-specific crossNAbs (Fig. 1) . Among the 20 infected children sampled at all three follow-up time-points, the plasma antibodies of 10 children (50 %) demonstrated cross-neutralizing activity as per the criteria defined above. Interestingly, at the third time-point follow-up, the plasma antibodies of six children were able to neutralize >80 % of the tier 2 viruses tested at an ID 50 !150: patient #1 (95 %), patient #2 (81 %), patient #13 (86 %), patient #14 (86 %), patient #15 (95 %) and patient #17 (95 %) (Fig. 1) . The plasma ID 50 titres for all the time-point samples of the 20 HIV-1-infected children, tested against a panel of 25 pseudoviruses, are given in Fig. S1 . Furthermore, a significant increase in neutralization breadth (Fig. 2a) and potency ( Fig. 2b) was observed with time in the 20 children. A consistent increase in the geometric mean titres (GMTs) of tier 1 and tier 2 viruses was observed with time ( Fig. 2c) . Overall, the neutralization frequency of the plasma antibodies in these children increased from 47.2 to 74.8 % in 500 virus/plasma combinations.
Development of cross-NAbs against diverse HIV-1 subtypes
We compared the GMTs of the plasma-neutralizing activity of the HIV-1-infected children (n=20) at baseline and in follow-up samples. The baseline plasma samples exhibited significantly higher GMTs for neutralization of subtype C viruses than non-subtype C viruses ( Fig. 3 ; P=0.01). Interestingly, in the third follow-up, the plasma GMTs were comparable for the subtype C and non-subtype C viruses ( Fig. 3 ; P=0.33), which suggests that cross-NAbs developed in the HIV-1-infected children over time.
All of the 20 HIV-1-infected donors were potential LTNPs, of which six (patient #1, patient #4, patient #13, patient #14, patient #15, patient #17) can be categorized as elite neutralizers (neutralizing three different HIV-1 subtypes at ID 50 >200). Furthermore, a positive correlation was found between neutralization breadth and viral load (Fig. S2) , suggesting that antigenic stimulation favours the development of neutralization breadth.
High prevalence of antibodies binding to consensus subtype C V3 peptide Improved anti-V3C Max 50 binding titres were observed in the first follow-up samples of patient #2, patient #4, patient #11 and patient #18, as compared to their baseline values. Further, the Max 50 binding titres either remained the same (patient #2) or improved with time (patient #4, patient #11 and patient #18) (Fig. S3b) . MPER-directed antibodies (against consensus subtype C or B MPER peptides) were absent in both the baseline and follow-up samples of the infected children (data not shown).
V3 peptide inhibition assay demonstrated V3-directed NAbs in patient #4
We performed the neutralization inhibition assay using subtype C consensus V3 peptide as the inhibitor to determine the contribution of the anti-V3 plasma antibodies of six elite neutralizers to the plasma cross-neutralizing activity. Despite the high Max 50 binding titres seen in ELISA, neutralization inhibition with V3C peptide was only observed in patient #4. No significant inhibition of plasma neutralization was observed in the other five elite neutralizers (Table S2 ).
Epitope mapping of patient #4 with overlapping V3C peptides We carried out the epitope mapping of patient #4 using V3C overlapping peptides. Based on the Max 50 ELISA binding titres, the immunoreactivity of patient #4 mapped to the tip of the V3 crown harbouring the GPGQ residues (Table S3 ).
V1.V2 glycan dependence of plasma antibodies in HIV-1-infected children We screened the plasma of 20 HIV-1-infected children at both baseline and first follow-up for their neutralization dependence on different glycans of the V1 and V2 region of HIV-1 gp120. We observed that the ID 50 titres of the baseline and follow-up samples of patient #3, patient #5 and patient #20 decreased by more than three-fold and two-fold, respectively, against various known V1.V2 N-glycan mutants compared to the respective wild-types, indicating the contribution of V1.V2-directed plasma antibodies to viral neutralization (Fig. S4) . The baseline and first followup plasma samples (95 %) efficiently neutralized the CAP256WT pseudovirus (ID 50 >200) and thus its corresponding N332A-glycan mutant was used to assess the presence of plasma antibodies targeting N332-glycan. However, the ID 50 neutralization titres of the baseline and first followup samples against the CAP256 wild-type and CAP256N332A mutant viruses did not differ by more than 1.5-fold for any of the 20 HIV-1-infected plasma samples (Fig. S5) , suggesting that these samples did not exhibit N332A glycan dependence for viral neutralization.
CD4 binding site-directed antibodies in crossneutralizing plasma The HIV-1-infected plasma samples were tested for the presence of CD4bs antibodies by ELISA binding using CD4bs-specific probes, RSC3WT and RSC3D371I mutant. The functionality of the CD4bs probes (RSC3WT and RSC3D371I) was verified in advance by ELISA (Fig. S6 ). An arbitrary cutoff for reciprocal Max 50 binding titres of 1000 with RSC3WT and a two-fold or more reduction in binding with mutant RSC3D371I was considered positive for the presence of CD4bs antibodies in the plasma samples. We found that 3 out of 20 baseline plasma samples (patient #2, patient #17 and patient #18) met the above criteria and showed binding with RSC3WT, while they did not bind with the mutant RSC3D371I protein (P<0.05) (Fig. 4 ). Among these, patient #2 and patient #18 exhibited 5.6-and 5.1-fold reductions, respectively, in binding affinity to RSC3D371I mutant compared to RSC3WT. On the follow-up, two samples, those from patient #17 and patient #18, showed improved reciprocal Max 50 binding with RSC3WT. Patient #18 exhibited the greatest fold reduction (7.7-fold) in binding affinity to RSC3D371I mutant compared to RSC3WT (Fig. 4) . Based on the binding and neutralizing results, patient #18 was chosen for further analysis of CD4bs-specific neutralizing determinants.
Three rounds of depletion were performed on each baseline and first follow-up plasma sample from patient #18 using RSC3WT and RSC3D371I mutant coupled beads. The depletion of RSC3WT-specific plasma antibodies was verified by a reduction in the ELISA binding of depleted as compared to undepleted plasma antibodies with JRFLgp120. We observed a depletion of 37 and 43 %, subtype C viruses at baselinerespectively, of CD4bs plasma antibodies with RSC3WT in the baseline and first follow-up plasma samples, which confirmed the presence of CD4bs antibodies in patient #18. BSA-coated beads were used as the specificity control (Fig. S7 ).
Patient #18's plasma contains CD4bs-directed NAbs
The CD4bs antibody ID 50 titres of the baseline and first follow-up samples from patient #18 after depletion on magnetic beads with RSC3WT are depicted in Table 2 .
The proportion of antigen-specific neutralization against a particular virus was assessed by calculating the percentage reduction in ID 50 as described previously [41] . Briefly, the RSC3WT-directed percentage neutralization against a particular virus was calculated using the formula: 100Â [(ID 50 titre of the flow-through of the BSA-coated beads We observed a considerable decrease in the neutralization capacity of the RSC3WT-depleted patient #18 plasma for both the baseline and first follow-up samples, suggesting that the neutralizing activity was directed against the CD4bs region. We considered a readout of >50 % of CD4bs-directed neutralizing activity as significant (Table 2 ). Du156.12 was most susceptible to neutralization, with 55 and 56 % being RSC3WT-directed neutralization in the baseline and first follow-up samples, respectively. For the MW965 virus, it was 50.6 and 53.0 %, while for SF162, 54.6 % and 52.0 % was RSC3WT-directed neutralization in the baseline and first follow-up samples, respectively. In the case of BL274, 52.7 and 50.8 % of neutralization was RSC3WT-directed in the baseline and first follow-up samples, respectively. Further, the results were confirmed by testing the neutralization activity of eluate from patient #18, after eluting the CD4bs-directed antibodies from magnetic beads coated with RSC3. Briefly, the antibodies adsorbed onto the RSC3WT and RSC3D371I mutant coupled beads were eluted and their concentration was determined. The neutralization activity of the eluted antibodies was measured against Du156.12 (subtype C) and SF162 (subtype B) viruses (Fig. 5 ). We observed nearly 2.6Â and 4Â less CD4bs-directed neutralization activity in RSC3D371I mutant eluate of the baseline and first follow-up samples, respectively, compared with that of the RSC3WT eluate, during testing against Du156.12. Similarly, with the SF162 virus, the antibody eluate from the RSC3D371I mutant of the baseline and first follow-up samples exhibited nearly 2.7Â and 3Â less neutralization activity, respectively, compared to the RSC3WT eluate, thus confirming the CD4bs-directed neutralization dependence of patient #18's plasma antibodies. We further confirmed the presence of CD4bs antibodies in patient #18's plasma by competitive ELISA with sCD4 (Fig. 6) and b12 (CD4bs NAb) to JRFLgp120, thereby confirming the CD4bs specificity of patient #18's plasma antibodies.
Evaluation for the presence of V3-directed plasma-NAbs, using a neutralization inhibition assay with V3C peptide against SF162 (subtype B) and Du156.12 (subtype C), revealed no evidence of linear-V3-specific IgG responses, with broadly neutralizing activity being seen in patient #18. This suggests that the highly reactive V3 antibodies seen in ELISA are non-neutralizing, which is consistent with previous studies that have shown limited neutralizing activity for linear-V3-specific IgG antibodies (Table S2 ). Further on, mapping for V1.V2 glycan dependence, we observed an approximately two-fold decrease in the plasma neutralization for patient #18 against a few V1.V2 N-glycan mutants (16055K171A, CAP45N160A and BG505N156A), which suggests that V1.V2-targeting antibodies might be contributing to the overall plasma neutralization for patient #18 (Fig. S4 ).
DISCUSSION
Reverse vaccinology employs information gained from extensive mapping of the epitope specificities of bnAbs, present in the plasma of selected HIV-1-infected donors, for the design of effective immunogens that can elicit similar antibodies in the vaccinees. Recently, we observed that the majority of the viruses circulating in chronic HIV-1-infected children were resistant to even some of the second-generation bnAbs [42] . This is of major concern in the context of the development of a protective HIV-1 vaccine that is effective in the paediatric population. Most of the HIV-1 infections in children are due to mother-to-child transmission [43] [44] [45] , hence it is imperative that protective vaccines in children should be able to block the transmitted/founder viruses. The extensive diversity of the viral envelope in different subtypes [8] , which may extend up to >30 % [46] , and also within the same subtype infecting different populations [47] [48] [49] , as observed in subtype C viruses in Indian and South African infected individuals, together with the absence of critical epitopes or their occlusion by nearby Nlinked glycosylation sites on the viral envelope [9, 50] , are some of the challenges faced in the development of an effective vaccine.
A recent IAVI Protocol C study conducted by Landais et al. in a large cohort of HIV-1-infected adults investigated the plasma neutralization potential and mapped the neutralizing determinants [51] . However, most of the studies on plasma NAb mapping have been conducted in HIV-1 subtype B-infected adults, with little information being available from non-subtype-Binfected adults and children [51] . This is the first longitudinal study to be conducted in this direction, evaluating the neutralizing activity and epitope specificities of plasma antibodies in a cohort of ART-naïve, chronic HIV-1-infected children from north India, with the predominant viruses circulating in the Indian population belonging to subtype C [52, 53] . In this study, 50% of the infected children demonstrated high titres of plasma NAbs at their baseline sampling that showed improvement in terms of breadth as well as potency with time against different HIV-1 subtypes. The subtype-matched neutralization (preferentially of subtype C viruses) by the baseline plasma antibodies in this study, as has also been reported previously in subtype C-infected children and adults [30, 54, 55] as well as in subtype B-infected adults [56, 57] , suggests that the epitopes eliciting such immune responses are both conserved and exposed on the circulating natural viruses.
Interestingly, on follow-up, the plasma antibodies of selected infected children exhibited an incremental increase in neutralization breadth and potency over time, which indicates a possible evolution of the circulating virus in these individuals. Our findings corroborate earlier observations which implied that certain common epitopes elicit subtype-specific NAbs and that a higher antigenic stimulation dictates the evolution of bnAbs [21, [58] [59] [60] [61] , which suggests that there is a need for repeated immunization with vaccines to ensure continued antigen-specific B cell stimulation and affinity maturation, which is an important feature of bnAbs [62, 63] . The development of cross-NAbs in the present cohort of chronically HIV-1-infected individuals shows that children are also able to elicit a potent neutralizing antibody response that is similar to what has been reported in adults. Further, the potent and broad neutralization response seen in six elite neutralizers, patient #1, patient #4, patient #13, patient #14, patient #15 and patient #17 (neutralizing three different HIV-1 subtypes at ID 50 >200), may plausibly explain their ability to contain disease progression. The neutralization inhibition by a V3C linear peptide seen in patient #18 shows that plasma V3-specific antibodies that target linear epitopes near or at the GPG crown motif contribute to its cross-neutralizing activity. Further, the binding of patient #4's plasma antibodies to a V3C crown containing GPGQ suggests that patient #4's plasma has 447-52D-like antibodies.
While linear V3-specific antibodies are immunodominant, they may not be the main neutralizing determinants [55, [64] [65] [66] , as has also been observed in the present study. V3 glycanspecific (N332) antibodies have recently been shown to demonstrate high potency and breadth (PGT121 and PGT128). In the present study, however, we did not find any N332-glycan dependence, as evidenced by the lack of neutralization dependence for the V3-glycan supersite. This is in contrast to the observations made by Cohen et al. [67] who reported a high frequency of glycan-dependent antibodies, including N332-glycan-targeting antibodies in chronic subtype C-infected individuals [67] . This could plausibly be due to screening of the plasma samples with only a single N332- glycan mutant pseudovirus. Autologous N332-glycan mutants and other V3-glycan supersite mutants would give greater insight into the epitopes contributing to N332-directed NAbs in the plasma of these infected children.
The CD4bs region of the HIV-1 envelope is highly conserved across the diverse viral strains and is an important target for the development of protective vaccines, as evidenced by the recently isolated CD4bs bnAbs, VRC01 [68] and 3BNC117 [69] , which have been found to confer protection in non-human primates [70] [71] [72] [73] [74] and in phase 1 human clinical trials [75] [76] [77] . Khouri et al. showed that low levels of CD4bs correlated with HIV-1 vertical transmission [78] . Hence CD4bs bnAbs need to be evaluated for their potential as prophylactic agents, especially in the context of preventing mother-to-child transmission of HIV. CD4bs antibodies are reported to be highly prevalent in adult subtype B HIV-1-infected individuals [18, 23, 79] , as compared to subtype Cinfected adults [51] . However, there is not a great deal of information available about the prevalence of CD4bs antibodies in HIV-1-infected children [32] . A salient finding of this study was the CD4bs-dependent crossneutralizing activity exhibited by patient #18's plasma antibodies, which persisted in the follow-up time-points, identifying this paediatric donor as a potential candidate for the isolation of CD4bs bnAbs. The low prevalence of CD4bs-directed antibodies observed in subtype C HIV-1-infected children of this study corroborates the findings of Landias et al., who reported CD4bs antibodies in only a handful of infected individuals in the protocol C study [51] . More studies with the purpose of understanding the various immunological factors associated with the development of CD4bs-directed antibodies will provide useful insights for the development of antibodies that are effective against multiple subtypes across all age groups.
In summary, this longitudinal study provides the first estimate of the prevalence of plasma NAbs and their epitope specificities in Indian HIV-1-infected children exhibiting plasma cross-neutralizing activity. In the majority of the ART-naïve chronic HIV-1-infected children, a relative increase in the breadth and potency of the plasma neutralization was observed over time. Dissecting the underlying mechanisms and the B cell biology involved in this improvement of the breadth and potency of the plasma NAbs in these HIV-1-infected children can provide new leads for vaccine development.
METHODS
Study subjects and ethics statement A total of 26 chronic HIV-1-infected ART-naïve children were recruited for this study and followed up for up to three time-points at the Pediatric Chest Clinic, Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India. However, follow-up sampling was only completed for 20 infected children, as two of the children were put on ART after the first follow-up, with another two following after the second follow-up, while two others declined to provide samples after the first follow-up, hence six children were excluded from the study. 
Virus-neutralization assays
The plasma samples from 20 ART-naïve HIV-1-infected children at baseline and follow-up were assessed for crossneutralization activity in a single-round HIV-1 envelope pseudovirus (200 TCID 50 ) infection of TZM-bl cells as described elsewhere [80] . Tier 2 pseudoviruses, belonging to subtypes A (n=3), B (n=7) and C (n=9), and tier 1 viruses belonging to subtypes B (n=1) and C (n=5), were used to measure plasma-neutralizing activity. HIV-1 envelope pseudoviruses were produced by co-transfecting HEK293T cells with HIV-1 envelopes containing an expression vector and an HIV-1 genomic vector (pSG3 delta env backbone) as detailed earlier [81] .
Neutralization assays were repeated twice and the average from the independent experiments was used to calculate the neutralization susceptibility of the virus. Murine leukaemia pseudotyped virus (MuLV) was used as a negative control.
Heat-map analysis based on clustering of plasma neutralization data
The NAb responses in the plasma samples at all time-points were determined by the heat-map tool using hierarchical clustering, freely available at the HIV Database (https:// www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap. html), which clustered the 20 HIV-1-infected samples and 25 HIV-1 viruses on the basis of natural log ID 50 values.
V1.V2 glycan-dependent neutralization
We assessed the glycan-directed neutralization of plasma antibodies using various V1.V2 N-glycan mutants. The neutralization potential of the plasma against wild-type pseudoviruses was compared with the corresponding N-glycan mutant to determine the fold dependence of neutralization on a particular glycan. 50 neutralization of more than three-fold and two-fold, respectively, for the baseline and follow-up samples against the mutant viruses was considered significant.
V3-glycan-directed antibodies
The neutralization dependence of the plasma antibodies on N332 glycan (in the V3 region of the viral envelope) was determined by assessing the neutralization efficiency of the plasma antibodies against CAP256 wild-type and its N332A mutant pseudovirus.
Antibody-binding assay (ELISA)
Binding of the plasma polyclonal antibodies against test peptides (V3B, V3C, MPER-B and MPER-C) was checked by ELISA as described previously [82] . The 50 % maximal binding of plasma antibodies (Max 50 ) was determined for those that showed saturation.
Next, the HIV-1-infected plasma from each subject was tested with RSC3WT and its RSC3D371I mutant to assess the presence of CD4bs antibodies and the Max 50 binding values were calculated as described previously [41] .
Peptide-inhibition neutralization assay
The assay protocol was similar to that described for the virus-neutralization assay, except that plasma dilutions of HIV-1-infected children were incubated for 1 h with subtype C consensus V3 peptide prior to the addition of virus. The final concentration of peptide in mixtures containing the plasma and virus was 30 µg ml
À1
. We performed the neutralization assay in the presence of consensus-C V3 peptide only (without adding plasma) to check for any possible effect of the peptide on viral infection.
Competitive ELISA with soluble CD4 (sCD4) To confirm the presence of CD4bs-specific plasma antibodies, competitive ELISA using sCD4 was performed as described previously [83] . Serially diluted control NAbs (b12 or 447-52D) and antibodies eluted from adsorbed RSC3WT-coated beads (RSC3WT eluate; starting at 1 µg ml
) were added to the JRFLgp120-coated plates in the presence and absence of a fixed concentration (20 µg ml À1 ) of sCD4 and incubated at room temperature for 1 h. Binding of NAbs or RSC3WT eluate antibodies (CD4bs-specific polyclonal antibodies) to JRFLgp120 was detected as described elsewhere [41] .
Coupling of protein on magnetic beads for depletion assay CD4bs antibodies from plasma samples were depleted using RSC3 conjugated to magnetic Dynabeads MyOne Tosylactivated (Invitrogen) as described previously [41] . RSC3WT, the parental wild-type protein, and the RSC3D371I mutant, which abrogates the binding of most CD4bs mAbs, were used. Bovine serum antigen (BSA)-coated beads served as a negative control. The CD4bs bnAb, VRC01, was used to verify the antigenic integrity of the RSC3WT coated on the magnetic beads (data not shown) by flow cytometry as described previously [41] .
Plasma CD4bs antibody-depletion assay Depletion of CD4bs plasma antibodies was performed as discussed previously [41] . To assess the depletion of CD4bs antibodies, BSA-coated beads were used as a negative control. Plasma antibodies bound to magnetic beads were eluted with 100 mM glycine-HCl elution buffer (pH 2.7) as described previously [41] .
Statistical analysis
Correlation tests were carried out using the Spearman rank correlation test. The Mann-Whitney U test was used for comparisons of two different groups. All statistical analyses were performed using GraphPad Prism software version 5.0 for Windows. A P-value <0.05 was considered significant. 
